Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1193MR)

This product GTTS-WQ1193MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1193MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8329MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ9815MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JS004
GTTS-WQ4416MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ14128MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ15557MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ1751MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
GTTS-WQ11454MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ1496MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW